Skip to content
    NAUT
    Earnings call· Jun 2026(Q2 FY26)

    Nautilus Biotechnology Q2 FY26 earnings call NAUT

    Jul 28, 2026 Source

    Executive summary

    Nautilus Q2 FY26 — Strategic Shift to Proteoforms Amidst Broad-Scale Delay

    Nautilus is strategically realigning its R&D resources, shifting focus and investment from its broad-scale proteome application to proteoform development due to strong customer demand and technical momentum. While the broad-scale application faces delays, the company is accelerating its proteoform roadmap, aiming for commercialization with instrument pre-orders in early 2027. Management is prudently managing cash and plans future fundraising to support this expanded proteoform strategy.

    Highlights

    5

    • Reported first revenue of $0.2 million in Q2 FY26, primarily from grant funding and early access programs.

    • Ended Q2 FY26 with $129.2 million in cash, supporting a runway into Q1 2028.

    • Operating expenses decreased 7% YoY to $15.9 million in Q2 FY26, coming in better than planned.

    • Proteoform development efforts are being tripled in headcount, accelerating content and capability development.

    • Alpha instrument data showed a median CV of 5.5% against an industry norm of 25%, demonstrating high resolution.

    Concerns

    3

    • Broad proteome application is behind schedule, with 2027 general availability at target specifications no longer expected.

    • Cash usage was $14.2 million in Q2 FY26, leading to anticipated fundraising between now and mid-2027.

    • Tau assay currently only supports brain tissue, limiting serviceable market size for neurodegeneration research.

    Guidance & targets

    14
    CategoryTargetConfidence
    Full-year 2026 Revenue
    approximately $0.5 million
    medium materiality
    High
    Full-year 2026 Operating Expenses Growth
    less than 10%
    medium materiality
    High
    Cash Runway
    into the 1st quarter of 2028
    high materiality
    High
    Beta Unit Placement
    on track to place a beta unit this year
    medium materiality
    High
    Voyager Platform Pre-orders
    open for pre-orders in early 2027
    high materiality
    High
    Voyager Platform Shipments
    beginning in mid-2027
    high materiality
    High
    Tau Proteoform Assay General Availability
    mid-2027
    medium materiality
    High
    AKT1 Proteoform Assay Early Access
    late 2026
    medium materiality
    High
    AKT1 Proteoform Assay General Availability
    mid-2027
    medium materiality
    High
    Second Oncology Proteoform Assay General Availability
    mid-2027
    medium materiality
    High
    Third Oncology Proteoform Assay General Availability
    late 2027
    medium materiality
    High
    Proteoform Assays Portfolio Expansion
    roughly 20 proteoform assays
    high materiality
    High
    Sample Input Reduction
    roughly 100-fold reduction
    medium materiality
    High
    Cerebrospinal Fluid (CSF) Support for Tau Assay
    enable cerebrospinal fluid for our tau assay in 2028
    medium materiality
    High

    Operational metrics

    14
    Total Revenue
    $0.2 million
    Q2 FY26

    First revenue reported, primarily from grant funding and early access programs.

    Total Operating Expenses
    $15.9 milliondown 7% YoY
    Q2 FY26

    Operating expenses decreased due to lower lab spending, stock-based compensation, and facilities costs.

    Research and Development Expenses
    $9.6 milliondown 8% YoY
    Q2 FY26

    Driven primarily by lower laboratory spending, lower stock-based compensation, and lower facilities costs.

    Selling, General, and Administrative Expenses
    $6.3 milliondown 6% YoY
    Q2 FY26

    Driven primarily by lower salaries, reduced incentive compensation expectations, and lower stock-based compensation.

    Cash, Equivalents, and Investments
    $129.2 millionvs $143.4 million at Q1 FY26 end
    Q2 FY26 end

    Balance at the end of the second quarter.

    Cash Usage
    $14.2 million
    Q2 FY26

    Cash used during the quarter.

    Alpha Instrument Median CV
    5.5%vs industry norm 25%
    Q2 FY26

    Demonstrates high sensitivity and reproducibility of the platform.

    Proteoform Development Team Headcount Change
    tripling
    Q2 FY26

    Reflects the strategic shift to accelerate proteoform development.

    Broad Scale Team Headcount Change
    reducing by roughly half
    Q2 FY26

    Resources reallocated to proteoform development.

    Application-Specific R&D Team Weighting
    2/3 proteoforms, 1/3 broad scalepreviously heavily weighted towards broad scale
    Q2 FY26

    New allocation of R&D resources reflecting the strategic shift.

    Sales Team Size
    3 people
    Q2 FY26

    Includes VP of Global Sales and two regional sales leaders.

    Voyager Instrument Price Point
    $1 million
    target

    Target price point for the Voyager platform, supported by market research.

    Assay Kit Price per Sample
    few thousand dollars
    target

    Target pricing for consumables.

    Oncology Market Size vs Neurodegeneration (Tissue Sample)
    5 to 10 times larger
    near term

    Due to higher prevalence of tissue samples in oncology compared to brain tissue in neurodegeneration.

    Industry KPIs

    4
    MetricValueDetails
    Revenue EPS guidance$0.5 millionUSD
    Pricing price realization$1 millionUSD
    Diagnostics testing demandProteoform measurements likely to translate directly into clinical research and diagnostics
    Instruments vs consumables services mixInflection point in instrument sales and consumables pull-through

    Deals & partnerships

    3
    Allen Institute for Brain ScienceCollaboration to analyze human brain samples for tau proteoforms.

    The collaboration aims to analyze human brain samples spanning multiple brain regions, genetic backgrounds, and disease severities using Nautilus's platform.

    Michael J. Fox FoundationGrant funding for alpha-synuclein proteoform assay development for Parkinson's disease.

    The foundation funded Nautilus to build the next proteoform assay for Parkinson's, specifically alpha-synuclein.

    Baylor College of MedicineFirst early access customer for tau proteoform assay.

    Baylor College of Medicine became Nautilus's first early access customer for the tau proteoform assay.

    Risks & headwinds

    4
    Broad proteome application delaynear to medium term

    2027 general availability at target specifications not supported

    Mitigation: Shifting majority of R&D resources to proteoforms; focused team continues to advance broad scale and reduce key technical risks.

    Cash burn and need for fundraisingmid-2027

    $14.2 million cash usage in Q2 FY26; cash runway into Q1 2028

    Mitigation: Prudent management of operating expenses; evaluating combination of debt and equity for fundraising when market conditions are optimal.

    Limited sample types for current assaysnear term

    Tau assay only supports brain tissue, leading to 9 out of 10 sales conversations being about CSF/blood support

    Mitigation: Developing capabilities for lower sample input (early 2027) and CSF support for tau (2028); oncology assays expected to support biofluids earlier.

    New sales cycles and commercialization pacenear term

    New sales team running new sales cycles

    Mitigation: Focusing on efficiency by concentrating on specific disease areas; leveraging unique technology to drive customer interest; expecting instrument demand to accelerate as portfolio broadens.

    What to watch in Q3 FY26

    5

    AKT1 Proteoform Assay Early Access

    late 2026
    CurrentIn development
    TargetEntry into early access

    Why it matters

    AKT1 is the first oncology proteoform assay and its entry into early access will validate the accelerated development timeline for oncology targets and open a new market segment.

    Our AKT1 proteoform assay is anticipated to enter early access in late 2026 with general availability expected in mid-2027.

    Q&A highlights

    5

    How will Nautilus balance its current cash runway and burn rate with the need to expand commercial teams to drive revenue, especially given the planned fundraising?

    Sujal Patel explained that the current commercial team is right-sized for the serviceable opportunity, focusing on efficiency by concentrating on specific disease areas like neurodegeneration and early oncology. He noted that the unique proteoform technology makes customers very receptive. Anna Mowry added that the company will raise funds when business catalysts and market conditions are optimal, emphasizing they are not in a rush.

    “We will raise when the combination of business catalysts and market conditions produces the best outcome for our company and our shareholders. To be clear though, we are not in a rush.”

    asked by Dan Brennan · answered by Anna Mowry

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Realignment to Proteoforms

    Nautilus is undertaking a significant strategic realignment, shifting a majority of its R&D resources from broad-scale proteome applications to proteoform applications. This decision is driven by strong customer enthusiasm for proteoform resolution and the unique biological insights it provides, as well as delays encountered in the broad-scale application development. The company believes this path offers the fastest route to commercialization and delivering unique value to the market.

    02

    Proteoform Momentum and Scientific Validation

    The company has observed growing customer enthusiasm for its proteoform approach, with feedback indicating a substantial commercial opportunity. Key milestones include a preprint demonstrating tau proteoform measurement at unprecedented🌐 resolution, collaborations with the Allen Institute and Michael J. Fox Foundation, and early access revenue from Baylor College of Medicine and the Michael J. Fox Foundation. The alpha instrument at the Buck Institute generated data with a median CV of 5.5% against an industry norm of 25%, revealing distinct tau proteoform signatures linked to ApoE genetic risk variants in Alzheimer's research.

    03

    Broad-Scale Application Delays and Future Outlook

    The broad proteome application is behind its original timeline, with assay configuration changes not sufficiently improving probe candidate performance to support a 2027 general availability at target specifications. While a focused team continues to advance the program and reduce technical risks, the majority of R&D resources are now directed to proteoforms. The company maintains that the underlying science for broad scale is sound, but a new timeline is not being provided at this time.

    04

    Oncology Focus with AKT1

    Nautilus has selected AKT1 as its first oncology proteoform assay, with EGFR and p53 also in development. AKT1 is prioritized due to its role as a control hub for cell growth and survival signaling, and the potential to improve patient selection for existing multi-billion-dollar AKT-targeted therapies by providing direct proteoform-level readouts. This demonstrates a repeatable assay building methodology, with oncology markers reaching the same technical bar in about one year that tau took five years to achieve.

    05

    Commercialization and Financial Strategy

    The sales team, currently at three people, is focused on engaging with customers, particularly for neurodegeneration (tau) and early oncology work. The company expects to open the Voyager platform for pre-orders in early 2027, with shipments beginning mid-2027, aligning with proteoform assay consumable releases. The instrument is targeted at a $1 million price point, with assay kits costing a few thousand dollars per sample. Nautilus anticipates fundraising between now and mid-2027, evaluating a combination of debt and equity to support proteoform expansion and market development.

    AI-generated summary of the company’s earnings call. Not investment advice.